Abstract:Schizophrenia is highly heritable and aggregating in families, but genetics alone does not exclusively explain the pathogenesis. Many risk factors, including childhood trauma, viral infections, migration, and the use of cannabis, are associated with schizophrenia. Adolescence seems to be the critical period where symptoms of the disease manifest. This work focuses on studying an epigenetic regulatory mechanism (the role of DNA methylation) and its interaction with mRNA expression during development, with a particular emphasis on adolescence. The presumptions regarding the role of aberrant neurodevelopment in schizophrenia were tested in the Methyl-Azoxy-Methanol (MAM) animal model. MAM treatment induces neurodevelopmental disruptions and behavioral deficits in off-springs of the treated animals reminiscent of those observed in schizophrenia and is thus considered a promising model for studying this pathology. On a gestational day-17, adult pregnant rats were treated with the antimitotic agent MAM. Experimental animals were divided into groups and subgroups according to substance treatment (MAM and vehicle agent [Sham]) and age of analysis (pre-adolescent and post-adolescent). Methylation and mRNA expression analysis of four candidate genes, which are often implicated in schizophrenia, with special emphasis on the Dopamine hypothesis i.e., Dopamine receptor D 2 ( Drd2 ), and the "co-factors" Disrupted in schizophrenia 1 ( DISC1 ), Synaptophysin ( Syp) , and Dystrobrevin-binding protein 1 ( Dtnbp1 ), was performed in the Gyrus cingulum (CING) and prefrontal cortex (PFC). Data were analyzed to observe the effect of substance treatment between groups and the impact of adolescence within-group. We found reduced pre-adolescent expression levels of Drd2 in both brain areas under the application of MAM. The "co-factor genes" did not show high deviations in mRNA expression levels but high alterations of methylation rates under the application of MAM (up to ~20%), which diminished in the further time course, reaching a comparable level like in Sham control animals after adolescence. The pre-adolescent reduction in DRD2 expression might be interpreted as downregulation of the receptor due to hyperdopaminergic signaling from the ventral tegmental area (VTA), eventually even to both investigated brain regions. The notable alterations of methylation rates in the three analyzed co-factor genes might be interpreted as attempt to compensate for the altered dopaminergic neurotransmission.

Reviewer #2 (public Review): Adolescent Neurostimulation of Dopamine Circuit Reverses Genetic Deficits in Frontal Cortex Function

Adolescent neurostimulation of dopamine circuit reverses genetic deficits in frontal cortex function

Adolescent chemogenetic activation of dopaminergic neurons leads to reversible decreases in amphetamine-induced stereotypic behavior

Alteration of Neuronal Excitability and Short-Term Synaptic Plasticity in the Prefrontal Cortex of a Mouse Model of Mental Illness.

Mtor Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons

Rewiring the future: drugs abused in adolescence may predispose to mental illness in adult life by altering dopamine axon growth

Reorganization of adolescent prefrontal cortex circuitry is required for mouse cognitive maturation

Continuous Performance Test Impairment in a 22q11.2 Microdeletion Mouse Model: Improvement by Amphetamine.

Pharmacological intervention in young adolescents rescues synaptic physiology and behavioural deficits in Syngap1+/− mice

Dopamine D1 receptors activation rescues hippocampal synaptic plasticity and cognitive impairments in the MK-801 neonatal schizophrenia model

Dopaminergic signaling regulates microglial surveillance and adolescent plasticity in the frontal cortex

The role of dopamine and endocannabinoid systems in prefrontal cortex development: Adolescence as a critical period

Reward modulation of cognitive function in adult attention-deficit/hyperactivity disorder: a pilot study on the role of striatal dopamine

Pharmacological modulation of developmental and synaptic phenotypes in human SHANK3 deficient stem cell-derived neuronal models

Frontal lobe synaptic plasticity in development and disease: modulation by the dopamine D1 receptor

Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence

Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events

Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice

Altered Axonal Targeting and Short-Term Plasticity in the Hippocampus of Disc1 Mutant Mice

Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunction

Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism